Warning: Invalid argument supplied for foreach() in /home/globaldi/public_html/modules/mod_banners/tmpl/default.php on line 9
 

Rockwell Medical, Inc. (RMTI) Files Form 4 Insider Buying : Robert L Chioini ... - Insider Trading Report PDF Print

Rockwell Medical, Inc. (RMTI): Robert L Chioini , CEO of Rockwell Medical, Inc. purchased 4,910 shares on Aug 14, 2015. The Insider buying transaction was disclosed on Aug 14, 2015 to the Securities and Exchange Commission. The shares were purchased at $11.96 per share for a total value of $58,723.60.

Currently the company Insiders own 5.5% of Rockwell Medical, Inc. Company shares. In the past six months, there is a change of 0% in the total insider ownership. Institutional Investors own 34.4% of Company shares. During last 3 month period, 25.61% of total institutional ownership has changed in the company shares. Rockwell Medical, Inc. (NASDAQ:RMTI): The stock price is expected to reach $ 16.6 in the short term. The number of analysts agreeing with this consensus is 5. The higher estimate for the short term price target is at $26 while the lower estimate is at $4. The standard deviation of the price stands at $7.99. The company shares have rallied 25.52% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $18.90 and the one year low was seen on Dec 15, 2014. The 50-Day Moving Average price is $15.83 and the 200 Day Moving Average price is recorded at $12.05. Rockwell Medical, Inc. (NASDAQ:RMTI) : On Monday heightened volatility was witnessed in Rockwell Medical, Inc. (NASDAQ:RMTI) which led to swings in the share price. The shares opened for trading at $14.15 and hit $14.53 on the upside , eventually ending the session at $14.09, with a gain of 0.86% or 0.12 points. The heightened volatility saw the trading volume jump to 533,528 shares. The 52-week high of the share price is $18.8999 and the company has a market cap of $708 million. The 52-week low of the share price is at $8.095 . Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patient’s bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.

...

 
Share |
Copyright © 2017 Global Dialysis. All Rights Reserved.